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Introduction
Fatigue is a common and often disabling symptom
among both mildly and severely affected adult patients
with Pompe disease. Our objective was to determine
whether enzyme replacement therapy (ERT) reduces
fatigue in adult patients with Pompe disease.
Methods
Data was collected as part of an international longitudi-
nal survey (‘IPA/ Erasmus MC Pompe Survey’). Fatigue
was measured with the Fatigue Severity Scale (FSS).
Repeated measurements ANOVA were used to analyze
the data over time. We also evaluated muscle strength
using the Medical Research Council (MRC) scale, mea-
sured pulmonary function as Forced Vital Capacity
(FVC), and assessed depression using the Hospital Anxi-
ety and Depression scale (HADS).
Results
We followed 163 patients for a median of 4 years before
ERT and for 3 years during ERT. At start of ERT, 68%
of patients were severely fatigued (FSS ≥ 5), against 55%
at their last follow-up. During ERT, mean FSS scores
declined significantly (-0.13 score points per year;
p<0.001) – a significant improvement on the period
before treatment (difference -0.14 FSS score-points per
year, p <0.01). Patients’ improvements in fatigue were
correlated with their response to ERT in muscle
strength (correlation coefficient: -0.55) and depression
(correlation coefficient: 0.34), but not with the effect of
ERT on pulmonary function.
Conclusion
Fatigue is a prominent symptom in adult Pompe disease.
Although it decreased during ERT, over half of the patients
remained severely fatigued after a median of 3 years of
therapy. To manage fatigue optimally in these patients,
ERT should therefore be combined with other strategies
that target fatigue. Further investigation is needed into the
exact role of muscle strength, depression and other factors
that may be associated with fatigue.
Published: 29 May 2013
doi:10.1186/1471-2474-14-S2-P16
Cite this article as: Güngör et al.: Enzyme replacement therapy and
fatigue in adults with Pompe disease. BMC Musculoskeletal Disorders 2013
14(Suppl 2):P16.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Departments of Pediatrics, Neurology and Clinical Genetics, Center for
Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center,
Rotterdam, The Netherlands
Güngör et al. BMC Musculoskeletal Disorders 2013, 14(Suppl 2):P16
http://www.biomedcentral.com/1471-2474/14/S2/P16
© 2013 Güngör et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
